September 30 Carlos Campoy Re: Employment Separation Dear Carlos:CytomX Therapeutics, Inc. • November 8th, 2022 • Pharmaceutical preparations
This letter (the "Agreement") confirms the terms of the offer made to you by CytomX Therapeutics, Inc. (the “Company”) regarding the separation of your employment, effective as of September 30, 2022 (the “Separation Date”) as a result of a reduction in force. If you sign and return this letter to me on or before November 14, 2022 it shall become a binding agreement between you and the Company, and you will receive the separation benefits described herein. If you do not timely sign and return it, or if you revoke it in accordance with the terms of Section 7(d), below, you will receive no payments or benefits from the Company after the Separation Date, including but not limited to Company-paid COBRA premium coverage.
MASTER CONSULTING AGREEMENTMaster Consulting Agreement • November 8th, 2022 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the “MCA”) is made and entered into by and between CytomX Therapeutics, Inc., a Delaware corporation, with an address at 151 Oyster Point Blvd, Suite 400, South San Francisco, CA 94080, (“Company”) and Carlos Campoy, located at [***] (“Consultant”), effective as of October 1, 2022 (“Effective Date”).
AMENDMENT NO 3 TOCollaboration and License Agreement • November 8th, 2022 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amendment Number 3 (the “Amendment”), effective as of October 11, 2022 (the “Amendment No 3 Effective Date”) amends that certain Collaboration and License Agreement entered into as of May 23, 2014 by and between CYTOMX THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, having its principal place of business at 151 Oyster Point Blvd., Suite 400, South San Francisco, CA, 94080 (“CytomX”), and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York, USA 10154 (“BMS”), as amended by Amendment Number 1 to Extend Collaboration and License Agreement, dated as of March 17, 2017 and Amendment Number 2, dated as of February 21, 2021 (collectively, the “Agreement”).
